Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Novel target and monoclonal antibody for early diagnosis and/or therapeutic intervention More
Naturally occurring compound shown to inhibit and reverse fatty liver. More
Anti-peptic ulcer, anti-gastritis More
A therapeutic peptide that can prevent intestinal infections by increasing the expression of MUC3 by intestinal epithelial cells. More
The University of Edinburgh has developed a new method of screening for polymorphs and solvates of drug compounds that has potential to revolutionise the way polymorph screening is conducted. More
Recently characterized MUC17 gene highly specific for pancreatic cancer. More
Diagnostic and potential therapeutic applications for mucin gene 4 (MUC4). More
Design, synthesis and biological evaluation of novel NO-releasing NSAIDs possessing a N-diazen-1-ium-1,2-diolate (NONOate), which offers additional advantages compared with organic nitrate-based NO-NSAIDs More
Scientists at the University of Edinburgh have identified a novel therapeutic strategy for the treatment of inflammatory disorders. More
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Appendicitis
- Cholangitis, sclerosing
- Colitis
- Colitis, ulcerative
- Constipation
- Crohn's disease
- Diarrhea
- Dyspepsia
- Electrolyte replacement
- Emesis
- Emesis, motion
- Esophagitis
- Flatulence
- Food poisoning
- Gastritis
- Gastroesophageal reflux disorder
- Gastrointestinal (other)
- Gastrointestinal secretions
- Gastroprokinetic
- Helicobacter pylori
- Inflammatory bowel disease
- Irritable bowel syndrome
- Nausea
- Pancreatitis
- Ulcer
- Ulcer, gastric
- Ulcer, gastroduodenal
- Ulcer, peptic
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us